- Molnupiravir
-
- $1.00
-
2026-09-17
- CAS:2492423-29-5
- Min. Order: 300g
- Purity: 99.8%
- Supply Ability: 20 TONS
- Molnupiravir
-
-
2026-07-28
- CAS:2492423-29-5
- Purity: 99.98%
- Supply Ability: 10g
|
| | Molnupiravir Basic information | | Uses |
| Product Name: | Molnupiravir | | Synonyms: | Uridine, 4-oxime, 5'-(2-methylpropanoate), (4Z)-;Molnupiravir-001-QA;Molnupiravir D7Q: What is
Molnupiravir D7 Q: What is the CAS Number of
Molnupiravir D7;MolnupiravirQ: What is
Molnupiravir Q: What is the CAS Number of
Molnupiravir Q: What is the storage condition of
Molnupiravir;((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate;Molnupiravir In-House;((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate (Molnupiravir Impurity);(2R,3S,4R,5R)-3,4-dihydroxy-5-[(4Z)-4-hydroxyimino-2-oxo-pyrimidin-1-yl]tetrahydrofuran-2-yl]methyl 2-methylpropanoate | | CAS: | 2492423-29-5 | | MF: | C13H19N3O7 | | MW: | 329.31 | | EINECS: | 100-001-2 | | Product Categories: | | | Mol File: | 2492423-29-5.mol |  |
| | Molnupiravir Chemical Properties |
| density | 1.62±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 100 mg/mL (303.67 mM; Need ultrasonic) | | pka | 6.71±0.20(Predicted) | | form | Solid | | color | White to off-white | | InChI | InChI=1S/C13H19N3O7/c1-6(2)12(19)22-5-7-9(17)10(18)11(23-7)16-4-3-8(15-21)14-13(16)20/h3-4,6-7,9-11,17-18,21H,5H2,1-2H3,(H,14,15,20)/t7-,9-,10-,11-/m1/s1 | | InChIKey | HTNPEHXGEKVIHG-QCNRFFRDSA-N | | SMILES | C(OC(=O)C(C)C)[C@H]1O[C@@H](N2C=C/C(=N/O)/NC2=O)[C@H](O)[C@@H]1O |
| | Molnupiravir Usage And Synthesis |
| Uses | Molnupiravir, also known as EIDD-2801/MK4482, is a ribonucleoside analog that can inhibit the replication of various RNA viruses. | | Description | Prodrug of antiviral nucleoside analog; inhibits SARS-CoV, SARS-CoV-2 and MERS-CoV infection. | | Definition | ChEBI: Molnupiravir is a nucleoside analogue that is N(4)-hydroxycytidine in which the 5'-hydroxy group is replaced by a (2-methylpropanoyl)oxy group. It is the prodrug of the active antiviral ribonucleoside analog N(4)-hydroxycytidine (EIDD-1931), has activity against a number of RNA viruses including SARS-CoV-2, MERS-CoV, and seasonal and pandemic influenza viruses. It is currently in phase III trials for the treatment of patients with COVID-19. It has a role as a prodrug, an anticoronaviral agent and an antiviral drug. It is a nucleoside analogue, an isopropyl ester and a ketoxime. It is functionally related to a N(4)-hydroxycytidine. | | Biological Activity | Molnupiravir is a broad-spectrum antiviral prodrug of the nucleoside analog β-D-N4-hydroxycytidine (NHC). It competes predominantly with CTP for incorporation; it induces lethal viral mutagenesis by increasing G to A and C to U transition mutations without inhibition of RNA synthesis in replicating coronaviruses, which prevents the development of viral resistance. In primary airway epithelial cell cultures, Molnupiravir dose-dependently inhibits SARS-CoV-2 infectious virus production; it also inhibits MERS-CoV and SARS-CoV with EC50 values in the submicromolar range. In mice infected with SARS-CoV or MERS-CoV, it improves pulmonary function, and reduces virus titer and body weight loss. Molnupiravir also displays in vivo efficacy against seasonal and pandemic influenza A shed virus. It is orally bioavailable. | | storage | Store at -20°C |
| | Molnupiravir Preparation Products And Raw materials |
|